Systemic or regional chemotherapy for liver metastases from colorectal cancer: Has the wheel stopped spinning?

Cancer Journal

Volumn 10, Issue 5, 2004, Pages 271-279

  Zalcberg, J R ^a   Kemeny, Nancy E ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Colorectal cancer; Intra arterial chemotherapy; Systemic therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CRYOSURGERY; HUMAN; LIVER METASTASIS; PATIENT SELECTION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL TUMOR; LIVER TUMOR; METASTASIS; PATHOLOGY; SURVIVAL;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; SURVIVAL ANALYSIS;

EID: 16644371526     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200409000-00001     Document Type: Review

References (56)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-543.
2. Perez N, Tournigand C, Maindrault-Goebel F, et al. Complete response after chemotherapy in advanced colorectal cancer (Abstr #1307). Proc Am Soc Clin Oncol 2003;22:325.
3. Cohen AD, Kemeny NE. An update on hepatic arterial infusional chemotherapy for colorectal cancer. The Oncologist 2003;8:553-566.
4. Jemal A, Murray T, Samuels A, et al. Cancer statistics 2003. CA Cancer J Clin 2003;53:5-26.
5. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer 1996;77:1254-1262.
6. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-321.
7. Finan PJ, Marshall RJ, Cooper EH, et al. Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer: a clinical and computer analysis. Br J Surg 1985;72:373-377.
8. Jefford M, Zalcberg J. Recent advances in the systemic therapy of metastatic colorectal cancer. Am J Cancer 2004; In press
9. Van Cutsem E, Dicata M, Wils J, et al. Recent advances in the management of colorectal cancer. Eur J Cancer 2001;37:2302-2309.
10. Khushalani N, McKinley BP, Gibbs JF, et al. Regional chemotherapy is indicated after surgical resection colorectal metastases to the liver: a debate. J Surg Oncol 2003;82:65-72.
11. Piedbois P, Michiels S. Survival benefit of 5-FU/LV over 5-FU bolus in patients with advanced colorectal cancer: an updated meta-analysis based on 2,751 patients (Abstr #1180). Proc Am Soc Clin Oncol 2003;22:294.
12. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998;16:301-308.
13. Kohne CH, Wils J, Lorenz M, et al. Randomized phase II study of high dose fluorouracil given as a 24 hour infusion with or without leucovorin versus bolus fluorouracil and leucovorin in advanced colorectal cancer (CRC): European Organization of Research and Treatment of Cancer Gastrointestinal Study Group. J Clin Oncol 2003;21:3721-3728.
14. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bi-monthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-815.
15. Buyse M, Thirion P, Carlson RW, et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000;356:373-378.
16. Meta-Analysis Group In Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996;88:252-258.
17. Harmantas A, Rotstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver: is there a survival difference? Meta-analysis of the published literature. Cancer 1996;78:1639-1645.
18. Kemeny N, Daly J, Reichman B, el al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Int Med 1987;107:459-465.
19. Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intra-arterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989;7:1646-1654.
20. Wagman LD, Kemeny MM, Leong L, et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990;8:1885-1893.
21. Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987;206:685-693.
22. Martin JK Jr, O'Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer, a randomized trial. Arch Surg 1990;125:1022-1027.
23. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long term results of a prospective randomized trial. J Clin Oncol 1992;10:1112-1118.
24. Allen-Mersh TG, Earlam S, Fordy C, et al. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994;344:1255-1260.
25. Lorenz M, Muller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000;18:243-254.
26. Kerr DJ, McArdle CS, Ledermann J, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomized trial. Lancet 2003;361:368-373.
27. Kemeny N, Niedzwiecki D, Hollis D, et al. Hepatic arterial infusion (HAI) versus systemic therapy for hepatic metastases from colorectal cancer: a CALGB randomized trial of efficacy, quality of life (QOL), cost effectiveness, and molecular markers (Abstr #1010). Proc Am Soc Clin Oncol 2003;22:253.
28. Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol 2002;29:119-125.
29. Scalhorn A, Peyerl G, Denecke H. Pharmacokinetics of fluorouracil isolated liver perfusion. Reg Cancer Treat 1988;1:21-27.
30. Kemeny N, Conti JA, Cohen A, et al. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 1994;12:2288-2295.
31. Campbell CA, Burns RC, Stizmann JV, et al. Regional chemotherapy devices: effect of experience and anatomy on complications. J Clin Oncol 1993;11:822-826.
32. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
33. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
34. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
35. Grothey A, Deschler D, Kroening K, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC) (Abst #512). Proc Am Soc Clin Oncol 2002;21:129.
36. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
37. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
38. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC (Abstr #3646). Proc Am Soc Clin Oncol 2003;22.
39. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
40. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
41. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412.
42. Rothenberg M, Cox J, DeVore R, et al. A Multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999;85:786-795.
43. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan, and fiuorouracil (5-FU)-leucovorin. J Clin Oncol 2003;21:2059-2069.
44. Kemeny N, Conti JA, Cohen A, et al. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 1994;12:2288-2295.
45. Kemeny N, Conti JA, Blumgart L, et al. Hepatic arterial infusion of floxuridine (FUDR), dexamethasone (Dex) and high dose mitomycin C (Mit C): comparable response to FUDR/leucovorin/Dex but with greater toxicity (Abstr #480). Proc Am Soc Clin Oncol 1995;14:201.
46. Safi F, Bittner R, Roscher R, et al. Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous therapy). Results of a controlled clinical trial. Cancer 1989;64:379-387.
47. O'Connell MJ, Nagorney DM, Bernath AM, et al. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J Clin Oncol 1998;16:2528-2533.
48. Kemeny N, Gonen D, Sullivan L, et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001;19:2687-2695.
49. Paty P, Fong Y, Harris R, et al. Update of phase I studies of hepatic arterial infusion (HAI) of floxuridine (FUDR) and dexamethasone (DEX) plus systemic oxaliplatin (Oxal) and irinotecan (CPT-11) or systemic Oxal fluorouracil (FU) and leucovorin (LV) for unresectable hepatic metastases from colorectal cancer (Abstr #1160). Proc Am Soc Clin Oncol 2003;22:289.
50. Portier G, Rougier P, Milan C, et al. Adjuvant systemic chemotherapy (CT) using 5-fluorouracil (FU) and folinic acid (FA) after resection of liver metastases (LM) from colorectal (CRC) origin. Results of an intergroup phase III study (trial FFCD-ACHBTH-AURC 9002) (Abstr). Proc Am Soc Clin Oncol 2002;21:133.
51. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039-2048.
52. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 2002;20:1499-1505.
53. Lorenz M, Muller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Ann Surg 1998;228:756-762.
54. Jamison RL, Donohue JH, Nagorney DM, et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 1997;132:505-511.
55. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990;77:1241-1246.
56. Fegiz G, Ramacciato G, Gennari L, et al. Hepatic resections for colorectal metastases: the Italian multicenter experience. J Surg Oncol 1991;2(Suppl):144-154.